Golden Analytics | $7,000,000 | (Apr 9, 2026)
HexemBio | $10,400,000 | (Apr 9, 2026)
E2 - Endovascular Engineering | $80,000,000 | (Apr 9, 2026)
Certified by Founder
Lodge
Exeliom Biosciences
start up
France
- Dijon, Bourgogne-Franche-Comté
- 21/07/2023
- Series A
- $8,898,320
At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
- Industry Pharmaceutical Manufacturing
- Website https://www.exeliombio.com/
- LinkedIn https://www.linkedin.com/company/nextbiotix/
Related People
Benjamin HadidaFounder
France -
Paris, Île-de-France
Biotech company builder and new therapeutic class explorer
True Footage | $40,000,000 | (Apr 9, 2026)
Petwealth | $1,700,000 | (Apr 9, 2026)
Pomo | $4,500,000 | (Apr 9, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
GoSats - The simplest onramp to Digital Assets in India | $5,000,000 | (Apr 9, 2026)
Life Biosciences | $80,000,000 | (Apr 9, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)